Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

Liraglutide

SAXAPCOS

Novo Nordisk · Phase 3 · Completed · Enrollment 88

NCT03480022

Y axis: Change in body weight from baseline, %

10500481216202436Liraglutide Pen Injector (Saxenda), week 32, 5.7%Liraglutide Pen Injector (Saxenda)Placebo liraglutide pen injector, week 32, 1.4%Placebo liraglutide pen injector

X axis: Weeks since randomization

Cited trial source. Only weeks the source states.

  • Liraglutide Pen Injector (Saxenda): week 32 5.7%
  • Placebo liraglutide pen injector: week 32 1.4%

One reported week is a point at that week. It is not a line from 0%. A solid line connects two or more reported weeks.